Author:
Badge Helen,Churches Tim,Naylor Justine M.,Xuan Wei,Armstrong Elizabeth,Gray Leeanne,Fletcher John,Gosbell Iain,Lin Chung-Wei Christine,Harris Ian A.
Abstract
AbstractPreventing avoidable venous-thrombo-embolism (VTE) is a priority to improve patient and service outcomes after total hip and total knee arthroplasty (THA, TKA), but compliance with relevant clinical guidelines varies. This study aims to determine the degree to which prophylaxis was compliant with Australian Orthopaedic Association (AOA) VTE prophylaxis guidelines and whether non-compliance is associated with increased risk of VTE. A prospective multi-centre cohort study of adults with osteoarthritis undergoing primary TKA/THA was completed at 19 high-volume public and private hospitals. Data were collected prior to surgery and for one-year post-surgery. Logistic regression was undertaken to explore associations between non-compliance with AOA VTE prophylaxis guidelines and symptomatic 90-day VTE outcomes. Data were analysed for 1838 participants from 19 sites. The rate of non-compliance with all clinical guideline recommendations was 20.1% (N = 369), with 14.1% (N = 259) non-compliance for risk-stratified prophylaxis, 35.8% (N = 658) for duration, and 67.8% (N = 1246) for other general recommendations. Symptomatic VTE was experienced up to 90-days post-surgery by 48 people (2.6%). Overall guideline non-compliance (AOR = 0.93, 95%CI = 0.4 to 1.3, p = 0.86) was not associated with a lower risk of symptomatic 90-day VTE. Results were consistent when people with high bleeding risk were excluded (AOR = 0.94, 95%CI = 0.44 to 2.34, p = 0.89). Non-compliance with the AOA VTE prophylaxis guidelines was not associated with risk of 90-day VTE after arthroplasty. This counterintuitive finding is concerning and necessitates a rigorous review of the AOA VTE prevention clinical guideline.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Kahn, S. R. & Shivakumar, S. What’s new in VTE risk and prevention in orthopedic surgery. Res. Pract. Thromb. Haemost. 4, 366–376. https://doi.org/10.1002/rth2.12323 (2020).
2. Gao, J. H., Chu, X. C., Wang, L. L., Ning, B. & Zhao, C. X. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine 96, e8059. https://doi.org/10.1097/md.0000000000008059 (2017).
3. Suen, K., Westh, R. N., Churilov, L. & Hardidge, A. J. Low-molecular-weight heparin and the relative risk of surgical site bleeding complications: Results of a systematic review and meta-analysis of randomized controlled trials of venous thromboprophylaxis in patients after total joint arthroplasty. J. Arthroplast. 32, 2911-2919.e2916. https://doi.org/10.1016/j.arth.2017.04.010 (2017).
4. Farfan, M. et al. Worldwide adherence to ACCP guidelines for thromboprophylaxis after major orthopedic surgery: A systematic review of the literature and meta-analysis. Thromb. Res. 141, 163–170. https://doi.org/10.1016/j.thromres.2016.03.029 (2016).
5. AOA Arthroplasty Society of Australia. Guidelines for VTE prophylaxis for hip and knee arthroplasty. https://arthroplasty.org.au/wp-content/uploads/2024/01/asa-guidelines-for-vte-prophylaxis-for-hip-and-knee-arthroplasty-february-2018.pdf (2018).